S100A4 and ovarian carcinoma: We analyzed the levels of serum MACC1 and S100A4 transcripts in a cohort of clinically documented ovarian cancer patients at primary diagnosis (n = 77) and compared it to the levels in serum of healthy controls (n = 25).